Alnylam Pharmaceuticals Stock Price - ALNY

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Alnylam Pharmaceuticals Inc ALNY NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 90.58 0.00 0.00 0.00 90.58 06:08:17
Bid Price Ask Price Spread Spread % News
79.00 118.00 39.00 33.05% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Alnylam Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 10.10B 111.49M $ -761.50M -7.56 - 110.95M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Alnylam Pharmaceuticals News

Date Time Source News Article
11/12/201916:00Business WireAlnylam to Webcast Presentation at Stifel 2019 Healthcare..
11/09/201912:00Business WireAlnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran..
10/31/201916:05Edgar (US Regulatory)Quarterly Report (10-q)
10/31/201908:11Edgar (US Regulatory)Current Report Filing (8-k)
10/31/201908:00Business WireAlnylam Pharmaceuticals Reports Third Quarter 2019 Financial..
10/24/201916:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
10/24/201914:11Business WireAlnylam Named #1 Biopharma Employer by Science Magazine

Latest ALNY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALNY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week91.1493.9889.7591.59473,271-0.56-0.61%
1 Month81.9993.9880.9488.94581,9998.5910.48%
3 Months83.9993.9873.3283.75624,7446.597.85%
6 Months69.1293.9865.8177.61677,53521.4631.05%
1 Year68.3296.0860.2778.87787,33422.2632.58%
3 Years47.69153.98535.9887.03942,11042.8989.93%
5 Years99.54153.98531.3884.15904,502-8.96-9.0%

Alnylam Pharmaceuticals Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis, Alnylam has partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Your Recent History
NASDAQ
ALNY
Alnylam Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191114 11:35:21